Orthocell Ltd has released a press release.
Trading Halt
Filed with ASX ·
On 6ix: 6ix.com/news/trading-halt-298
6ix hasn’t read this filing yet.
Story so far
Earlier from Orthocell
- Another Record Revenue Quarter for Orthocell
- First Distributor signed for Remplir in $75m Canadian Market
- Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery
- Remplir Use in Prostate Surgery Signals Global Opportunity
- Remplir™ Study Delivers Compelling 81% Success Rate
Later from Orthocell
- $30m Placement Sees Orthocell Positioned for Rapid Growth
- OCC Secures Rights to High-Value Bone Regeneration Tech
- HK Distributor Signed as Remplir Expands in the Asian Market
- Remplir Launches in Hong Kong with First Surgical Case
- 2nd Distributor in Canada, Entire $75m Market Now Covered
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell